PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29504722
OWN - NLM
STAT- MEDLINE
DCOM- 20180312
LR  - 20180312
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 9
DP  - 2018 Mar 1
TI  - Breast-Cancer Recurrence after Stopping Endocrine Therapy.
PG  - 870
LID - 10.1056/NEJMc1715968 [doi]
FAU - Anderson, Geoffrey M
AU  - Anderson GM
AD  - University of Toronto, Toronto, ON, Canada [email protected]
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Receptors, Estrogen)
RN  - 094ZI81Y45 (Tamoxifen)
SB  - AIM
SB  - IM
CON - N Engl J Med. 2017 Nov 9;377(19):1836-1846. PMID: 29117498
CIN - N Engl J Med. 2018 Mar 1;378(9):870-871. PMID: 29490180
MH  - Antineoplastic Agents, Hormonal
MH  - *Breast Neoplasms
MH  - Chemotherapy, Adjuvant
MH  - Humans
MH  - *Neoplasm Recurrence, Local
MH  - Receptors, Estrogen
MH  - Tamoxifen
EDAT- 2018/03/06 06:00
MHDA- 2018/03/13 06:00
CRDT- 2018/03/06 06:00
PHST- 2018/03/06 06:00 [entrez]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/03/13 06:00 [medline]
AID - 10.1056/NEJMc1715968#SA1 [pii]
AID - 10.1056/NEJMc1715968 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Mar 1;378(9):870. doi: 10.1056/NEJMc1715968.